Search
Now showing items 1-3 of 3
Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.
(Wiley, 2017-09-01)
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV ...
Ombitasvir / paritaprevir / ritonavir / dasabuvir ± ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .
(Wiley, 2017-03-29)
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV ...
'Real-life' experience with direct-acting antiviral agents for HCV after kidney transplant
(Elsevier, 2021-11)
Abstract
Introductions and objectives: The introduction of direct-acting antiviral (DAA) agents promises to change dramatically the management of hepatitis C in kidney transplant recipients, a patient group where the ...